Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Industry Group: Pharmaceuticals
Country/Region: China
Identifier: SHG:600276
Jiangsu Hengrui Pharmaceuticals Co Ltd is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs and anti-infection medications. It specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 514 out of 850
Universe
Global Universe 10937 out of 15080
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
| Company | ESG Risk Rating | Industry Rank |
|---|---|---|
| Haleon Plc |
14.7
Low
|
14 out of 850 |
| DSM-Firmenich AG |
16.8
Low
|
39 out of 850 |
| Takeda Pharmaceutical Co., Ltd. |
21.3
Medium
|
108 out of 850 |
| Otsuka Holdings Co., Ltd. |
23.2
Medium
|
148 out of 850 |
| Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
30.6
High
|
514 out of 850 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
How do the ESG Risk Ratings work?
Top Material ESG Issues for Jiangsu Hengrui Pharmaceuticals Co., Ltd.
Understand how exposed companies are to specific material ESG issues and how well companies are managing these issues.
What are Material ESG Issues?
Material ESG issues are issues that are considered to be financially material to a given company in a relevant sub-industry.
Controversy Rating
Highest Controversy level that has impacted Jiangsu Hengrui Pharmaceuticals Co., Ltd.'s ESG Risk Rating in the last three years
Highest Controversy Level
Contributing Events
Highest Controversy Events Locations
